Progressive stent technologies: new approaches for the treatment of cardiovascular diseases
Source: Expert Opinion on Drug Delivery, Volume 3, Number 6, November 2006 , pp. 783-797(15)
Publisher: Informa Healthcare
Abstract:The CYPHER® (Cordis, Johnson & Johnson) sirolimus-eluting stent and the TAXUS® (Boston Scientific) paclitaxel-eluting stent have been extensively evaluated and have been proven to be significant novel tools for the treatment of coronary artery disease. Several sirolimus derivatives have already emerged, receiving CE Mark approval. However, in the future, it is likely that drugs presently under investigation will address additional mechanisms associated with neointimal formation, either as single agents or in combination with antiproliferative compounds. Concurrently, alterations on stent platform design (helicoidal, open-closed cell), coatings (biodegradable, bioabsorbable, nanoporous) and polymers are being explored.
Document Type: Research Article
Affiliations: 1: 1Interventional Cardiologist, Department of Interventional Cardiology, Thorax centre, Erasmus Medical Centre, Rotterdam, The Netherlands 2: 2Professor of Interventional Cardiology, Thoraxcentre, Ba 583, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands., Email: email@example.com
Publication date: 2006-11-01